" Thy-1 " cells another 5 weeks and then declined. A 2-week course of thrice weekly injections of human Steel factor, interleukin and long-term culture-initiating cells (LTC-IC) in the bone marrow of some sublethally irradiated severe combined im-(IL)-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoietin (administered just before the munodeficient (SCID) mice transplanted intravenously with normal human marrow cells, and the subsequent finding mice were killed for analysis) did not alter the pace of regeneration of either primitive or mature human hematopoietic that the NOD/LtSz-scid/scid (NOD/SCID) mouse supports higher levels of human cell engraftment, we undertook a cells, or their predominantly granulopoietic and B-lymphoid pattern of differentiation, although a significant enhancing series of time course experiments to examine posttransplant changes in the number, tissue distribution, cycling activity, effect on the level of human cell engraftment sustained after 3 months was noted. Cycling studies showed the human and in vivo differentiation pattern of various human hematopoietic progenitor cell populations in this latter mouse CFC present at 4 to 5 weeks posttransplant to be rapidly proliferating even in mice not given human growth factors. model. These studies showed typical rapid posttransplant recovery curves for human CD34
T colony-forming potential in vitro, as well as multiple lineagerestricted and more mature cell types, including those be-HROUGHOUT ADULT LIFE, the bone marrow maintains a population of primitive hematopoietic cells that can permanently regenerate the entire blood-forming system. longing to the erythroid, granulopoietic, and B lymphoid pathways. 12, 13, 15 In addition, it was found that injections of In mice, this activity is routinely evaluated by transplanting cells into hematologically compromised (usually myehuman growth factors enhanced the subsequent production of human hematopoietic cells regardless of whether the loablated), syngeneic recipients, and this has formed the basis of procedures for quantitating 1 and characterizing murine growth factor injections were started immediately posttranshematopoietic stem cells. [2] [3] [4] [5] In humans, analysis of the size plant or 3 months later. 12 More recently, the gene marking and composition of clonal populations occasionally seen in studies of Nolta et al, 16 using beige-nude-X-linked immunorecipients of normal marrow allografts has shown that they deficiency (bg, nu, xid) mice as recipients, have provided also contain transplantable totipotent stem cells. 6 However, progress in characterizing these human cells and their regulation has been limited by a paucity of models suitable for in cally 7 or genetically [8] [9] [10] [11] immunodeficient. In recent studies
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These studies indicated that at least some human hematopoi- transplanted mice was determined as described in detail previously. 32 Hematopoietic cell cultures. Assays for granulopoietic, eryBriefly, aliquots of the cells to be tested were first incubated in throid, and multilineage (granulocyte-erythroid-macrophage-megaserum-free Iscoves medium for 20 minutes in each of two tubes, karyocyte) colony-forming units (CFU-GM, BFU-E, and CFUone with and one without 20 mCi/mL of high specific activity 3 H-GEMM, respectively) were usually performed by plating cells in Tdr. The cells were then washed and plated in the same methylcellu-FCS-containing (30%) methylcellulose media (Stem Cell), to which lose media described above to detect surviving CFC. The proportion 3 U/mL Ep (Stem Cell), 50 ng/mL SF (Amgen, Thousand Oaks, of CFC in S-phase was then calculated from the difference in colony CA) and 20 ng/mL each of IL-3, GM-CSF (both from Sandoz), Gyields from the two cell suspensions. 32 Because the test cell popula-CSF (Stem Cell) and IL-6 (Cangene, Mississauga, Ontario, Canada) tions were always first selected on the basis of their reactivity with were added as a source of growth factors. On a few occasions, an antihuman CD34 antibody and in some cases also had to be when CD34
/ human cells could not be isolated from the mouse shipped from Toronto to Vancouver for analysis, all cell cycle studies cell suspensions being evaluated (for either practical or quantitative were performed on cells that had been incubated at 4ЊC overnight reasons), half of the FCS in the methylcellulose medium was reafter being removed from the mice. To test whether this would affect placed with an equivalent volume of a pretested pool of equivalently the results obtained, a series of control experiments were performed. supportive normal human serum and the G-CSF and IL-6 were omitFor these, freshly isolated light density normal human blood cells ted to minimize the stimulation of murine clonogenic cells. 12 The were mixed 1:1 with mouse bone marrow cells and then incubated different categories of human colonies known to be generated under at 4ЊC for 24 hours before being sorted and assayed as for test either of these conditions were scored in situ after 2 to 3 weeks of samples. These experiments showed that this had no effect on the incubation at 37ЊC using well established criteria.
cycling status of the human CFC (data not shown) which, in normal LTC-IC assays were initiated by suspending initial or sorted blood, are a totally quiescent population.
CD34
/ human cells in myeloid LTC medium (Myelocult, Stem Cell) DNA extraction and analysis. High molecular weight DNA was supplemented with 10 06 mol/L freshly dissolved hydrocortisone isolated from the bone marrow of transplanted mice, EcoRI digests (Sigma Chemicals, St Louis, MO) and then seeding the cells onto of genomic DNA (1 mg) loaded into each lane and the blots hybridpreformed ''feeder'' layers consisting of a 1:1 mixture of irradiated ized with a human chromosome 17-specific a-satellite probe (p17H8) M210B4 and S1/S1 mouse fibroblast cell lines, which had been as previously described. 12 The proportion of human cells in each genetically engineered to produce human SF (4 ng/mL), G-CSF (190 sample was then inferred from the intensity of the characteristic 2.7 ng/mL), and IL-3 (4 ng/mL).
30 These LTC-IC assay cultures were kb band obtained relative to those obtained on the same blot from a series of artificial mixtures of human and mouse DNA (ranging then maintained at 37ЊC for 6 weeks with weekly half media changes, from 0.1% to 50% human DNA). at the end of which, all cells were harvested 31 and appropriate aliquots plated for CFC determinations. LTC-IC numbers were calcu-RESULTS lated from the total CFC numbers detectable in these cultures after
Demonstration of human CD34
/ Thy-1
/ cells and LTC-IC
6 weeks assuming that on average, each human LTC-IC produces 18 CFC detectable after 6 weeks using these LTC-IC assay condiin CB17/SCID mice and the lack of effect of exogenous For personal use only. on October 3, 2017. by guest www.bloodjournal.org From ately high, consistent with the existence in these mice of suboptimal conditions for the support of later stages of human hematopoiesis. 12 To determine whether repeated exogenous administration of various human growth factors could improve the number of human CD34 / Thy-1 / cells or LTC-IC obtained in these mice, in the two experiments in which 4 1 10 7 human marrow cells were transplanted, additional CB17/SCID mice were injected with either PIXY321 (7 mg/mouse) and human Ep (20 U/mouse), or human SF (10 mg/mouse), every other day until the mice were killed. However, there was no evidence of a consistent effect of these growth factors on any compartment of human hematopoietic cells evaluated including CD34
/ Thy-1 / cells and LTC-IC. Representative results from one experiment are illustrated in Fig 3. In this case, Southern analysis was used to compare the proportion of human cells (DNA) present in the marrow of four mice, one of which had been given PIXY321 plus Ep and the other three, no growth factors.
Comparison of the extent of human cell engraftment in various strains of immunodeficient mice. In another series of experiments, we compared the ability of CB17/SCID mice to support human hematopoiesis with that of three other strains of immunodeficient mice (BEIGE/SCID, RAG-2 0/0, and NOD/SCID). The BEIGE/SCID and NOD/SCID mice were given 350 to 400 cGy and the RAG-2 0/0 mice, a radiobiologically approximately equivalent dose of 1,200 cGy at a low dose rate of 1.5 cGy/minute or 700 to 800 cGy at a dose rate of 100 cGy/minute. A total of 1 to 4 1 10 7 human marrow cells per mouse were then transplanted into these different strains and the total number of human cells present in the marrow 4 to 10 weeks later assessed either by DNA analysis or flow cytometry. In the four strains compared, more consistent and higher numbers of human cells were routinely detected in the NOD/SCID recipients con- firming previous preliminary findings. 15 At no time was evi- / Thy-1 / human cells (Fig 1) were evident in the row. A detailed time course study of the rate and pattern marrow of six of nine CB17/SCID mice examined between of engraftment of NOD/SCID mice transplanted with a fixed 4 and 7 weeks posttransplant. CD34
/ LTC-IC were also innoculum of 2 1 10 7 human marrow cells was then underdetected, but even less frequently. Time course studies taken. Figure 5A to C show the pooled results from eight showed that very few of the injected cells (õ1% of all experiments (eight groups of individually analyzed mice, (CD45/CD71) / cells) were detectable in the marrow of the each group transplanted with cells from a different human CB17/SCID mice 2 days posttransplant and that plateau marrow donor) in which the kinetics of regeneration of the numbers of all types monitored appeared to be reached total population of human hematopoietic cells (ie, expressing within 2 weeks (Fig 2) . In addition, it can be seen that the proportion of CD34 / cells in these mice was disproportion-CD45 and/or CD71, Fig 5C, as the total population of human CD34 / cells and various the spleen of the NOD/SCID mice when they were analyzed 2 days posttransplant and in total, these represented õ1% phenotypically and functionally defined subpopulations of human CD34
/ cells (ie, total CFC, LTC-IC, and CD34 / of the original transplant (Fig 5C top) . After this time, all populations increased rapidly and in parallel. However, in Thy-1 / cells). Human CD34 0 CD19 / (B-lineage) cells were also evaluated, but in a single experiment only. The solid contrast to the results obtained in the CB17/SCID recipients (Fig 2) , the numbers of human cells present in the NOD/ symbols in Fig 5A to C delineate the kinetics of repopulation seen in the marrow. The open symbols show the correspond-SCID mice did not plateau after 2 weeks, but rather continued to increase rapidly for another 2 to 3 weeks. Maximum ing results for the spleen, which were determined in four of the same experiments. As seen previously in the time course numbers of the most primitive human cell types monitored (CD34 / Thy-1 / cells, CFC, and LTC-IC) were seen at this studies of CB17/SCID repopulation by human cells (Fig 2) , õ2% of any of the cell types injected could be found in time (ie, 5 weeks posttransplant). The more mature populations of human hematopoietic cells (total CD34 / cells, total either of the two hind legs (two femurs / two tibias) or in of all the nucleated cells in the blood, were CD34 / (Fig 5D) . also exceeded the number of cells of the corresponding type
In some of the time course experiments, additional mice in the original transplant. By 16 weeks posttransplant (when were injected with a cocktail of human growth factors 3 these experiments were terminated), all populations of hutimes a week for the 2 weeks immediately preceding their man cells had declined significantly. Nevertheless, because assessment. This cocktail consisted of 10 U Ep/mouse/injecof the high levels of human hematopoiesis regenerated tion, 10 mg/mouse/injection of SF, and 6 mg/mouse/injection within the first 2 1/2 months posttransplant, most types of each of IL-3 and GM-CSF. Groups of mice treated in this primitive cells could usually still be detected after 4 months.
way were killed and assessed at each of the same time points The relative numbers of different types of human CFC as the nongrowth factor-injected controls described above. detected also changed with time posttransplant due to the fact that all stages of human erythropoiesis appear to be These studies failed to show any obvious effect of these poorly supported in these mice ( Table 2 , columns III and IV).
growth factor injections on the number of human cells proThis effect was most obvious in the more mature erythroid duced during the regenerative phase, ie, before 10 weeks progenitor compartments and was more pronounced during posttransplant in any tissue (data not shown). However, as the latter 2 months of declining human hematopoiesis than shown in Fig 6, by 16 weeks, all populations of human during the first 2 months (column I). Thus, by 7 weeks myeloid progenitor cells in the marrow were, on average, posttransplant, human CFU-E were usually no longer detectsignificantly (P õ .05) more numerous in mice that had able, despite the fact that substantial numbers of primitive received the injections of human growth factors than in those BFU-E were measured for up to 16 weeks (É 3% of all that had not. Nevertheless, the magnitude of the increases CFC detected). In contrast, human granulopoiesis appeared resulting from growth factor injection (É fivefold to 20-fold) to proceed normally with no alteration in the ratio of primiwere not sufficient to completely counteract the 50-fold to tive to mature types of granulopoietic progenitors throughout 100-fold decline of all types of human cells that occurred in the entire period of follow-up by comparison to the original control mice starting 8 to 10 weeks posttransplant (Fig 5) . human marrow cell suspensions transplanted (column II).
In addition, although some of the factors injected are known Multilineage human progenitors were also detectable at evto selectively stimulate erythropoiesis (eg, Ep), there was no ery time point and were maintained at approximately the evidence of an improved differentiation of human progenisame frequency (relative to other types of CFC).
In four of these experiments, blood was also collected tors along this pathway in the growth factor-injected mice.
AID Blood 0009 / 5h37$$$161 05-13-97 20:46:22 blda WBS: Blood factors. In a first series of experiments, we investigated whether the human CFC populations detectable in the early Changes in the cell cycle status of human CFC present Four types of comparisons are shown (I, II, III, IV). Column I shows the relative numbers of CFU-E (E), mature BFU-E (mB), and primitive BFU-E (pB) as a proportion of the total erythroid CFC population (E / mB / pB). Column II shows the ratio of mature (m) to primitive (p) CFU-GM (GM) in the total CFU-GM population detected. Column III shows the relative numbers of different types of primitive CFC, and column IV shows the relative numbers of all erythroid-restricted (E / B), granulopoietic-restricted (GM) and multilineage (GEMM) CFC as a fraction of the total human CFC population detected at each time point. CFC measurements are from the same 8 experiments shown in Fig 5. Criteria used for distinguishing primitive and mature subclasses of BFU-E and CFU-GM are given in 
Growth factors (10 mg SF, 6 mg IL-3, 6 mg GM-CSF, 10 U Ep) injected 31/mouse/week for 2 weeks before being killed.
3 H-Tdr suicide studies showed that all CFC detectable in the marrow of the NOD/SCID mice 4 weeks posttransplant were rapidly proliferating (Table 3 ) and this included both the primitive erythroid and the primitive granulopoietic subsets that, in the marrow of normal adults, are largely quiescent. 
DISCUSSION
The data we report here provide new evidence that the human cells detectable in the hematopoietic tissues of immuphase of engraftment (ie, 4 weeks posttransplant) would nodeficient mice transplanted with normal adult human marshow the increased cycling characteristics expected of a rerow cells are the progeny of a primitive subset. Such cells generating population 35, 36 or alternatively, whether they can clearly home into and respond to signals generated by would still be segregated into proliferating and quiescent the hematopoietic microenvironment of the murine marrow compartments according to their proliferative potential (as and spleen, which then cause a rapid expansion of both displayed in methylcellulose assays), which is a characterisprimitive and more differentiated types of human hematopoietic cells. This was perhaps best exemplified by the huge tic of these cells in steady-state human marrow. 32, 33 Standard / cells, CFC, and levels of human cell engraftment would involve a more rapid production of mature human hematopoietic cells, whose abil-LTC-IC. Indeed, for many of these populations, the levels attained just in the two hind legs of the transplanted mice ity to secrete various species-specific growth factors might then further enhance the extent of human hematopoietic cell (ie, É 25% of the total marrow volume of the mouse 34 ) 5 to 10 weeks posttransplant exceeded the total number of recovery stimulated by endogenous murine factors. Detection of a stimulating effect of exogenously supplied growth such cells in the original innoculum injected. Of particular note was the observation that human hematopoietic cells factors might then be restricted to situations where the number of human cells transplanted was relatively reduced, a with a very primitive cell surface phenotype (CD34 / Thy-1 / ), as well as those that could be functionally identified possibility consistent with the present observation of no growth factor effect on the first 3 months of engraftment in as CFU-GEMM and as LTC-IC, showed the same dramatic regrowth kinetics as later cell types, but reached peak values mice transplanted with relatively high numbers of cells.
In summary, we have demonstrated the feasibility of using approximately 1 month earlier.
The continuing presence of these primitive human cells the NOD/SCID mouse as a recipient for routine experimental studies of human hematopoiesis in an in vivo setting. The at readily detectable levels even 4 months posttransplant provides additional strong evidence that these mice are iniobserved kinetics of human cell engraftment, the extensive range of primitive and mature cell types produced including tially engrafted by totipotent human stem cells with longterm in vivo repopulating potential, which then undergo exboth lymphoid and myeloid lineages, and characteristic changes in the cycling activity of early clonogenic cell types tensive self-renewal to regenerate and sustain these related populations. Some evidence of human hematopoietic stem obtained within the hematopoietic tissues of these mice are all hallmarks of the regeneration pattern expected from transcell self-renewal in NOD/SCID mice reconstituted with human cord blood cells has recently been obtained from experiplantable hematopoietic stem cells of syngeneic origin. This model should therefore serve as a useful starting point for ments with secondary transplants. 37 The initially high proliferative activity in vivo of both primitive and mature types the further characterization of such cells in human tissues, as well as opening up new opportunities for investigating of CFC, as well as the fact that large numbers of more mature CD34 0 human cells expressing CD45 and/or CD71 could their regulation and responses to novel manipulations or treatments in vivo. be maintained in the mice 4 months after injection, would also indicate a continuous process of hematopoietic cell proliferation and differentiation, ultimately from a very primi-Moreover, the inability of repeated injections of multiple tion and purification of a primitive hematopoietic cell type in adult growth factors that are known to stimulate erythropoiesis mouse marrow capable of lympho-myeloid differentiation in longboth in vitro and in vivo to correct this deficiency in erythroterm marrow ''switch'' cultures. Blood 86: 1339, 1995 poiesis suggests that other factors may limit the differentia- 
